Panacea Biotec Limited share price
NSE: PANACEABIO · ISIN INE922B01023
Key numbers
- Market cap
- ₹ 2,282 Cr
- Current price
- ₹ 372.60
- 52-week high / low
- ₹ 647 / 292
- Stock P/E
- -
- Book value
- ₹ 128.4
- Dividend yield
- 0.00%
- ROCE
- -0.2%
- ROE
- -0.6%
- Debt to equity
- 0.02
- Sales growth (3 yrs)
- 10.1%
- Profit growth (3 yrs)
- -
- 1-year return
- -8.5%
About Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 167 | 141 | 165 | 167 | 200 |
| Operating profit | -1 | -18 | 12 | 3 | 6 |
| Net profit | 4 | -14 | 4 | 1 | 2 |
| EPS (₹) | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 |
Peers in Biotechnology
Data for information only, not investment advice. Prices end of day.